December 12, 2022

Star8 Corp. Has moved and more

Tampa, Dec. 12, 2022 (GLOBE NEWSWIRE) — Star8 Corp. (OTCPK: STRH) is please to announce that the corporate headquarters has officially moved to the Tampa Urban Centre at Westshore, located at 4830 West Kennedy Blvd., Suite 600, Tampa, Florida, 33609. The facility allows us great flexibility for meeting and the ability to expand when it become necessary. Additionally, the headquarters is closer to Hyper 30 Data operations, which allows better control and management.

Secondly, we are activity reviewing the qualifications of number of independent auditing firms, and I expect to announce the engagement within a few days. Completing an audit of our Company is important for two reasons, 1) to become a fully reporting entity, and 2) be up-listed OTCqb.

Thirdly, our Company, through the acquisition of Hyper 30 Data is now focused on one industry. The IT and Security industry. This industry is in high demand and will result in growth and profits. This places our Company in the position to achieve growth and profits.

Fourthly, we have identified additional companies for acquisition and are currently reviewing these potential entities, which are within the IT and Security industry. Additional announcements will come shortly after LOI is executed.

For more information about Star8 Corp.’s please visit Star8Corp.com. To learn more about Hyper 30 Data, visit hyper30data.com.

About Star8 Corporation

Star8 Corporation (OTCPK: STRH) is a publicly traded company with expertise in IT and security. Additionally, Star8 Corp. provides sustainable marketing, technology, sales and distribution consulting for clients. To learn more about star8 Corp. please visit Star8Corp.com.

For inquiries please contact: info@star8corp.com | 1-866-316-0808

Investor Inquiries:
Star8 Corp.
1-866-316-0808

FORWARD LOOKING INFORMATION

This press release contains forward-looking statements and information that are based on the beliefs of management and reflect the Company’s current expectations. When used in this press release, the words “estimate”, “project”, “belief”, “anticipate”, “intend”, “expect”, “plan”, “predict”, “may” or “should” and the negative of these words or such variations thereon or comparable terminology are intended to identify forward-looking statements and information. The forward-looking statements and information in this press release includes information relating to the implementation of the Company’s business plan. Such statements and information reflect the current view of the Company with respect to risks and uncertainties that may cause actual results to differ materially from those contemplated in those forward-looking statements and information.

By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following risks: risks associated with the implementation of the Company’s business plan and matters relating thereto, risks associated with the cannabis industry, competition, regulatory change, the need for additional financing, reliance on key personnel, the potential for conflicts of interest among certain officers or directors, and the volatility of the Company’s common share price and volume. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made, and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change. Investors are cautioned against attributing undue certainty to forward-looking statements.

There are a number of important factors that could cause the Company’s actual results to differ materially from those indicated or implied by forward-looking statements and information. Such factors include, among others, risks related to the Company’s proposed business, such as failure of the business strategy and government regulation; risks related to the Company’s operations, such as additional financing requirements and access to capital, reliance on key and qualified personnel, insurance, competition, intellectual property and reliable supply chains; risks related to the Company and its business generally. The Company cautions that the foregoing list of material factors is not exhaustive. When relying on the Company’s forward-looking statements and information to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. The Company has assumed a certain progression, which may not be realized. It has also assumed that the material factors referred to in the previous paragraph will not cause such forward-looking statements and information to differ materially from actual results or events. However, the list of these factors is not exhaustive and is subject to change and there can be no assurance that such assumptions will reflect the actual outcome of such items or factors. While the Company may elect to, it does not undertake to update this information at any particular time.

THE FORWARD-LOOKING INFORMATION CONTAINED IN THIS PRESS RELEASE REPRESENTS THE EXPECTATIONS OF THE COMPANY AS OF THE DATE OF THIS PRESS RELEASE AND, ACCORDINGLY, IS SUBJECT TO CHANGE AFTER SUCH DATE. READERS SHOULD NOT PLACE UNDUE IMPORTANCE ON FORWARD-LOOKING INFORMATION AND SHOULD NOT RELY UPON THIS INFORMATION AS OF ANY OTHER DATE. WHILE THE COMPANY MAY ELECT TO, IT DOES NOT UNDERTAKE TO UPDATE THIS INFORMATION AT ANY PARTICULAR TIME EXCEPT AS REQUIRED IN ACCORDANCE WITH APPLICABLE LAWS.

GlobeNewswire Distribution ID 8712845

December 12, 2022

General Fusion exceeds core technology performance targets with plasma and compression prototypes

The company achieves performance milestones that demonstrate it is on track to meet its Fusion Demonstration Program goals at power plant relevant scale

Compression system (CWC)

General Fusion’s primary compression prototype has completed over 1,000 shots, consistently achieving its compression performance targets.

VANCOUVER, British Columbia, Dec. 12, 2022 (GLOBE NEWSWIRE) — General Fusion has demonstrated plasma energy confinement times, plasma temperatures, and compression system performance that support meeting its goal of 10 keV (100 million degrees Celsius) in the company’s integrated Magnetized Target Fusion (MTF) demonstration, being built to 70 percent scale of a commercial machine at the UK Atomic Energy Authority’s Culham Campus.

The results come as the company celebrates its 20^th anniversary. In that time, it has completed over 200,000 plasma shots, achieved 150 patents and patents pending, and grown to a team of more than 200 employees. Using large-scale prototypes, General Fusion has proven its core technology approach. Today, it announces additional advancements in its plasma and compression technologies.

“In 2002, I founded General Fusion with the vision of creating a technology that would combat climate change and end the world’s reliance on fossil fuels for power. To be successful, I knew I needed a practical method that overcame longstanding barriers to commercializing fusion. That’s why I chose Magnetized Target Fusion,” said Dr. Michel Laberge, Founder and Chief Science Officer, General Fusion. “After 20 years – to see our core technologies proven out and ready to be put together in the fusion demonstration – it’s an incredible feeling.”

Creating fusion energy with MTF starts with a hydrogen plasma injected into a vessel lined with liquid metal. Next, high-powered pistons compress the liquid metal around the plasma, squeezing and building pressure until the plasma reaches more than 100 million degrees Celsius – and fusion occurs. The technology depends on three core factors to be successful: hot plasmas that hold their energy long enough to be compressed, a synched compression system, and a stable fusion process that will increase neutron yields and temperatures when plasmas are compressed.

Plasma Injector (PI3)

General Fusion’s plasma injector exceeds requirements with 10-millisecond self-sustaining energy confinement time without requiring active magnetic stabilization, auxiliary heating, or a conventional divertor.

Plasma injector exceeds requirements with 10-millisecond self-sustaining energy confinement time:

General Fusion’s plasma injector PI3 is the world’s largest and most powerful of its kind. It generates plasma targets with confinement times exceeding predictions from accepted scaling laws and consistently achieves the conditions required for the company’s fusion demonstration. Today, General Fusion is creating the plasmas it needs, achieving 10 millisecond energy confinement time without requiring active magnetic stabilization, auxiliary heating, or a conventional divertor. The plasmas reach a temperature of 250 eV, almost 3 million degrees Celsius, the starting plasma temperature required for the company to compress the plasma to fusion conditions. Combined with known scaling laws, these results and modelling provide confidence that the company’s fusion demonstration is on track to meet its target temperature of 10 keV.

Compression system prototype validates five millisecond compression time for fusion demonstration:

General Fusion takes a pulsed approach to create fusion energy. This means, unlike a tokamak, its plasmas do not need to be sustained for long periods. Instead, the company uses mechanical compression to achieve fusion conditions. This is done with high-speed drivers that are timed to rapidly create a precisely shaped, symmetrical collapse of a liquid metal cavity, which envelopes the plasma. General Fusion’s primary compression prototype has completed over 1,000 shots, consistently achieving its compression performance targets. In addition, researchers and engineers have used test results across a range of compression parameters to validate and refine their fluid dynamic models to a high degree of fidelity. These models show that the fusion demonstration can achieve a shaped collapse in a liquid metal cavity within approximately five milliseconds. This is sufficient for the thermal confinement times already achieved within General Fusion’s existing plasma prototypes.

These two recent milestone announcements build on the significant technological advances previously achieved by General Fusion’s team since the founding of the company in 2002.

2005: Fusion reaction in the company’s first MTF prototype
2010: First at-scale plasma injector with magnetically confined plasma
2011: First demonstration of compressive heating of magnetized plasma
2012: Liquid metal compression tests validate engineering of liquid metal approach and synchronization of at-scale pistons
2013: Plasma achieves performance to enable compression heating
2017: Stable compression of plasma
2018: Heating and increased neutron yield during plasma compression
2019: Plasma lifetime maintained within a liquid metal cavity
2019-2021: Plasma performance sufficient to achieve fusion conditions at scale
2021: Compressed liquid cavity into a controlled, symmetrical shape sufficient to achieve fusion conditions when scaled in the company’s fusion demonstration
2022: Plasma energy confinement time of 10 milliseconds and validated compression time of 5 milliseconds support achieving 10 keV at power plant scale

“Commercializing fusion energy is within reach, and General Fusion is ready to deliver it to the grid by the 2030s,” said Greg Twinney, CEO, General Fusion. “We have the right team, the right technology, and the right strategy to get us there.”

About General Fusion
General Fusion pursues a fast, efficient, and collaborative path to practical fusion power. We are completing an aggressive development plan to deliver economical carbon-free fusion energy with our proprietary Magnetized Target Fusion technology by the 2030s. Our mission is supported by a global syndicate of leading institutional investors, venture capital firms, and technology pioneers, together with governments across North America and Europe. General Fusion collaborates with a global network of partners to create a sustainable future built on cleaner energy, better materials, and a comprehensive life cycle approach to the world’s infrastructure. Founded in 2002, we are headquartered in Vancouver, Canada, with additional centers co-located with internationally recognized fusion research laboratories near London, U.K., and Oak Ridge, Tennessee, U.S.A. Learn more at www.generalfusion.com.

General Fusion Media Relations
media@generalfusion.com
+1-866-904-0995

Follow General Fusion

twitter.com/generalfusion

instagram.com/generalfusion

linkedin.com/company/general-fusion

facebook.com/generalfusion

youtube.com/c/GeneralFusionInc

A video accompanying this announcement is available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/40e62c52-a2f3-4f00-a25d-144a71e16433

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/d5188480-b50f-479c-b906-c804563f3e3f

https://www.globenewswire.com/NewsRoom/AttachmentNg/0422f5df-2c53-4196-870a-1c16517a3e65

GlobeNewswire Distribution ID 8712402

December 12, 2022

New Oceana Analysis Finds Tuna Fisheries Are Masking USD $411 Million Blue Shark Industry

Oceana calls on regional fishery management organizations and member states to comprehensively manage the fishing of blue sharks

WASHINGTON, Dec. 12, 2022 (GLOBE NEWSWIRE) — A new Oceana-commissioned study reveals that vessels authorized to fish in the waters of designated tuna regional fishery management organizations (RFMOs) are operating major shark fisheries, propping up a massive blue shark (Prionace glauca) commercial fishery with a landing value worth USD $411 million. This first-of-its-kind analysis shows the catch value of blue shark exceeds that of each of the three iconic bluefin tuna fisheries. The report confirms blue shark represents 60% of all reported global shark catches, singularly dominating both the shark fin and meat trade, while direct management of the species remains absent.

Last month at the Convention on International Trade in Endangered Species, world leaders voted to provide protections for 60 shark species, including blue sharks. This decision means these species can only be traded if their stocks are proven to be sustainably managed. Except for a 2019 catch limit set under the jurisdiction of the International Commission for the Conservation of Atlantic Tunas (ICCAT) RFMO, blue sharks are fished without any limits. “Despite being considered one of the most resilient and abundant shark species, blue shark populations are threatened by poor management,” said Philip Chou, Oceana’s Senior Director of Global Policy. “Without proper management, blue sharks and the ecosystems they balance face a perilous future. Direct and active fishery management of blue sharks must begin immediately.”

This report analyzed global data on the catch, trade, and management of sharks and tuna reported to the Food and Agriculture Organization and RFMOs. Researchers led by Poseidon Aquatic Resource Management Ltd. found that nearly 200,000 metric tons of blue shark were legally caught and landed in 2019, amounting to over 7 million blue sharks. Of that catch, 90% was brought in by large-scale commercial fleets, mostly longliners, with 74% flagged to distant-water fishing nations. Spain and Taiwan are responsible for roughly half the total blue shark catch.

To access Oceana’s summary and the full report, visit oceana.org/blueshark. This research was prepared for Oceana’s Transparent Oceans Initiative — an international program that illuminates the global footprint of the world’s distant-water fishing fleets, catalyzing policy change to protect the ocean and the communities who rely on it.

Contact: Anna Baxter, abaxter@oceana.org

GlobeNewswire Distribution ID 8711327

December 12, 2022

AGC Biologics and Gore Collaborate on New Protein A-based Purification Technology and Contract Manufacturing Services for Antibody Therapies

GORE® Protein Capture Devices and AGC Biologics development and manufacturing platforms help advance downstream purification and support effective development and manufacturing

Seattle, Dec. 12, 2022 (GLOBE NEWSWIRE) — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a collaboration with W.L. Gore & Associates (Gore) that features Protein A affinity purification technology from Gore alongside the CDMO’s contract development and manufacturing services.

By using GORE and AGC Biologics, biopharmaceutical companies can improve downstream purification processes through increased productivity of the Protein A step, enabling a full single-use downstream process, which can eliminate column bioburden from storage, reduce manufacturing footprint, and help lower costs for clinical manufacturing and select scale commercial manufacturing.

The collaboration includes the family of GORE® Protein Capture Devices with Protein A, which improves productivity in Protein A affinity purification, and provides high binding capacity at short residence times, alongside AGC Biologics’ mAb-based CDMO services. The joint offering from Gore and AGC Biologics is available across various sites in the AGC Biologics’ network.

“This is a notable example of how our technology can support antibody-based therapies coming to market by addressing bottlenecks and boosting productivity” said William Barrett, Ph.D., Product Specialist, for GORE PharmBIO. “Our portfolio of GORE Protein A Capture Devices, with a unique expanded polytetrafluoroethylene (ePTFE) membrane, offers a scalable solution and we are thrilled to work with ACG Biologics so customers can reach their next clinical or commercial milestones.”

AGC Biologics’ scientists have several decades of R&D experience in the monoclonal antibody space. The company has established more than 200 mammalian and microbial cell culture-based products. AGC Biologics’ historic work in implementing early-on high-throughput titer assessments of monoclonal cell lines helps streamline its early-phase mAb product programs.

“Investments in new technologies like the GORE Protein Capture Device are important to meet our clients’ needs and address the changes in the monoclonal antibody market,” said Kasper Møller, Chief Technical Officer of AGC Biologics. “We are excited to offer this new technology for GMP manufacturing at relevant scales throughout our manufacturing network.”

Learn more about GORE Protein Capture Devices with Protein A and get the latest information on upcoming events at www.gore.com/capturemoremAbs.

To learn more about AGC Biologics’ cell line development services, visit https://www.agcbio.com/capabilities/process-development/cell-line-development.

Learn more about AGC Biologics’ full line of mammalian-based manufacturing services at https://www.agcbio.com/capabilities/mammalian.

Attachment

AGC Biologics & GORE Advance Biologics Manufacturing

Nick McDonald
AGC Biologics
14254193555
nmcdonald@agc.com

GlobeNewswire Distribution ID 8712011

December 12, 2022

OKX Introduces Quick Transfer Feature & Announces Ledger Compatibility, Streamlining Self-Custody for Millions of Users

VICTORIA, Seychelles, Dec. 12, 2022 (GLOBE NEWSWIRE) — OKX, the world-leading cryptocurrency platform, has introduced the seamless Quick Transfer feature and announced Ledger hardware wallet compatibility to streamline self-custody for millions of users.

The Quick Transfer feature allows OKX users to easily transfer assets between the OKX exchange and its leading self-custody Web3 Wallet. Quick Transfer is now available on the OKX Android Mobile App and will soon be available on iOS.

Later in December, OKX will introduce Ledger hardware wallet compatibility with its OKX Mobile App, making it the only multi-chain wallet that supports the Ledger hardware wallet on a mobile app. Users will be able to manage their crypto across 40+ chains and access DEX, NFT Marketplace, dApps and Yield directly from their hardware wallet. Ledger and Trezon compatibility is currently available on the OKX Wallet Web Extension.

The OKX Web3 Wallet is a decentralized multi-chain wallet that gives users custody of their own assets. OKX does not store user passwords, seed phrases (mnemonics), or private keys, nor does it send them to external servers. Additional benefits of the OKX Web3 Wallet include:

The ability to hold cryptocurrencies and NFTs across over 40 blockchains such as Bitcoin, Ethereum, OKC, Solana, BSC, and Aptos
Built-in access to a multi-chain, cross-chain decentralized exchange (DEX) that uses smart routing to get users the best rates across protocols
A multi-chain, zero-fee NFT marketplace that aggregates collections across other marketplaces like OpenSea, MagicEden, LooksRare, etc.
A service that finds the best on-chain yield to make DeFi accessible to all

OKX Director of Financial Markets Lennix Lai said: “Self-custody has been rising in importance in the crypto sector for some time, and this has accelerated in recent months. At OKX, we’re building a unified experience across Web3 and centralized services in a single app. Quick Transfer enables easy-to-use asset transfer, and ensures a seamless and secure experience, while Ledger compatibility empowers customers to take self-custody a step further by utilizing hardware wallets. Customers using these services will have more custody choices as well as direct access to and greater control of their assets.”

Find out more about the importance of self-custody here.

For further information, please contact:
Media@okx.com

About OKX
OKX is the second biggest global crypto exchange by trading volume and a leading web3 ecosystem. Trusted by more than 20 million global customers, OKX is known for being the fastest and most reliable crypto trading app for investors and professional traders everywhere.

Beyond OKX’s exchange, the OKX Wallet is the platform’s latest offering for people looking to explore the world of NFTs and the metaverse while trading GameFi and DeFi tokens.

To learn more about OKX, download our app or visit: okx.com

GlobeNewswire Distribution ID 8712771